{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T07:49:35Z","timestamp":1785916175114,"version":"3.56.0"},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T00:00:00Z","timestamp":1785801600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014584","name":"Universit\u00e4tsmedizin der Johannes Gutenberg-Universit\u00e4t Mainz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014584","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thrombosis J"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In recent years, establishing multidisciplinary pulmonary embolism response teams (PERTs\/EXPERT-PE) has become more prevalent. A survey was conducted to assess the availability and structure of PERTs in German and European hospitals. A survey was circulated among German hospital centers with cardiovascular expertise to obtain data on their current PE treatment approaches, the existence and features of PERTs, their activation methods, and their structural organization. Additionally, data regarding PE treatment priority relative to acute coronary syndrome and the availability of outpatient PE follow-up programs was gathered. Results were compared with those of European PE reference centers. Overall, 65 hospitals participated at this German survey with most PERTs available at university hospitals (63%), especially in West (63%) and Southern (62%). Although 61.5% of the German centers handle over 40 PE cases annually, only 52.3% of those hospitals already implemented a PERT, which is low in comparison to a European Survey among PE reference centers (80.8%). In 86% cases, PERT is led by Cardiology, followed by Angiology (6.9%), Pulmonology (4.6%), and Critical Care Medicine (2.3%). Regarding advanced treatment the majority of hospitals performed catheter-directed thrombolysis (72.2%) and catheter-based thrombectomy\/aspiration (74.1%). A follow-up program for patients with PE is considerable higher in European reference centers opposed to German hospitals. This survey demonstrated that among large German cardiovascular centers PERTs are markedly less often present compared to European PE reference centers. Additionally, in German centers, PE follow-up programs are not widely implemented. This emphasizes the pressing need for awareness campaigns for acute and chronic PE.<\/jats:p>","DOI":"10.1186\/s12959-026-00872-7","type":"journal-article","created":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T11:35:07Z","timestamp":1785843307000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrating pulmonary embolism response teams: perspectives and outcomes from a European and German survey analysis"],"prefix":"10.1186","volume":"24","author":[{"given":"Lukas","family":"Hobohm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Stannek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis T.","family":"Farmakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Tichelbaecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Lurz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Perings","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stavros","family":"Konstantinides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingo","family":"Ahrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,4]]},"reference":[{"issue":"9","key":"872_CR1","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1161\/CIRCRESAHA.115.306841","volume":"118","author":"AM Wendelboe","year":"2016","unstructured":"Wendelboe AM, Raskob GE. Global burden of thrombosis: epidemiologic aspects. Circ Res. 2016;118(9):1340\u20137.","journal-title":"Circ Res"},{"issue":"4","key":"872_CR2","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1093\/eurheartj\/ehz236","volume":"41","author":"K Keller","year":"2020","unstructured":"Keller K, Hobohm L, Ebner M, et al. Trends in thrombolytic treatment and outcomes of acute pulmonary embolism in Germany. Eur Heart J. 2020;41(4):522\u20139.","journal-title":"Eur Heart J"},{"issue":"5","key":"872_CR3","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1378\/chest.13-1562","volume":"144","author":"C Kabrhel","year":"2013","unstructured":"Kabrhel C, Jaff MR, Channick RN, Baker JN, Rosenfield K. A multidisciplinary pulmonary embolism response team. Chest. 2013;144(5):1738\u20139.","journal-title":"Chest"},{"key":"872_CR4","doi-asserted-by":"crossref","unstructured":"Hobohm L, Farmakis IT, Keller K, et al. Pulmonary embolism response team (PERT) implementation and its clinical value across countries: a scoping review and meta-analysis. Clin Res Cardiol. 2022:1\u201311.","DOI":"10.1093\/eurheartj\/ehac544.1891"},{"issue":"1","key":"872_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s11239-018-1737-8","volume":"47","author":"R Rosovsky","year":"2019","unstructured":"Rosovsky R, Chang Y, Rosenfield K, et al. Changes in treatment and outcomes after creation of a pulmonary embolism response team (PERT), a 10-year analysis. J Thromb Thrombolysis. 2019;47(1):31\u201340.","journal-title":"J Thromb Thrombolysis"},{"key":"872_CR6","unstructured":"Rosenfield K, Klok FA, Piazza G, et al. Ultrasound-facilitated, catheter-directed fibrinolysis for acute pulmonary embolism. N Engl J Med. 2026."},{"issue":"1","key":"872_CR7","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s11239-020-02188-3","volume":"51","author":"R Annabathula","year":"2021","unstructured":"Annabathula R, Dugan A, Bhalla V, Davis GA, Smyth SS, Gupta VA. Value-based assessment of implementing a Pulmonary Embolism Response Team (PERT). J Thromb Thrombolysis. 2021;51(1):217\u201325.","journal-title":"J Thromb Thrombolysis"},{"key":"872_CR8","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.amjcard.2025.04.017","volume":"249","author":"MH Maqsood","year":"2025","unstructured":"Maqsood MH, Zhang RS, Rosenfeld K, et al. Do Pulmonary embolism response teams for acute pulmonary embolism improve outcomes? insights from a meta-analysis. Am J Cardiol. 2025;249:71\u201382.","journal-title":"Am J Cardiol"}],"container-title":["Thrombosis Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12959-026-00872-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-026-00872-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12959-026-00872-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T07:20:14Z","timestamp":1785914414000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12959-026-00872-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,4]]},"references-count":8,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["872"],"URL":"https:\/\/doi.org\/10.1186\/s12959-026-00872-7","relation":{},"ISSN":["1477-9560"],"issn-type":[{"value":"1477-9560","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,4]]},"assertion":[{"value":"16 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Since this survey was aimed at medical professionals and did not involve the collection of personal, private, or sensitive information, patient data, human experimentation, or clinical trials, it did not require formal approval by an ethics committee.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"L. Hobohm reports lecture\/ consultant fees from MSD, Boston Scientific, INARI, Penumbra, and Johnson&Johnson, outside the submitted work. K. Stannek reports no conflicts of interest. K. Keller reports no conflicts of interest. I.T. Farmakis reports no conflicts of interest. T.Tichelb\u00e4cker has received lecture honoraria from Inari and travel expense eimbursements. P. Lurz has received institutional fees and research grants from Abbott Cardiovascular, Edwards Lifesciences, and ReCor; has received honoraria from Edwards Lifesciences, Abbott Medical, Innoventric, ReCor, Boehringer Ingelheim, and Daiichi-Sankyo; and has stock options with Innoventric. C. Perings reports no conflicts of interest. S.V. Konstantinides reports research grants or contracts to his institution from Bayer AG, Daiichi Sankyo, Boston Scientific Corp., Penumbra Inc., Getinge, and Inari Medical\/Stryker; and personal consulting fees from Daiichi Sankyo, Boston Scientific Corp., Penumbra Inc., MSD, Novartis, and Inari Medical\/Stryker, all outside the submitted work. I. Ahrens reports lecture\/consultant fees from Bayer HealthCare, Boeringer Ingelheim, Bristol-Myers Squibb\/Pfizer, Daiichi Sankyo, and Boston Scientific.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"73"}}